The Christie NHS Foundation Trust — CureCurrent

How to interpret these research links

Connected source records

The exact organization name The Christie NHS Foundation Trust appears in 36 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials36

Recruiting shown4

Roles2

SourceClinicalTrials.gov

Clinical trials

36 shown

A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)NCT05903430 · lead sponsor · 2025-08-29

Chronic Radiation Induced Bowel Toxicity StudyNCT06640959 · lead sponsor · 2024-11-19

Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the LungNCT07202260 · lead sponsor · 2025-07-03

ACTIVE_NOT_RECRUITING

A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast CancerNCT04188119 · lead sponsor · 2023-12-01

NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNtsNCT04960059 · lead sponsor · 2022-02-11

Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)NCT05702619 · lead sponsor · 2021-10-03

Lung Screening in People Cured of Hodgkin LymphomaNCT04986189 · lead sponsor · 2021-08-01

Impact on Quality of Life From Multi-modality Lung CancerNCT04540757 · lead sponsor · 2020-11-25

Impact of COVID-19 on Lung Cancer PatientsNCT04538456 · lead sponsor · 2020-10-15

Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative StudyNCT04396119 · lead sponsor · 2020-02-11

A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast CancerNCT03794596 · lead sponsor · 2019-09-01

Personalised Disease Monitoring in Metastatic Breast CancerNCT04597580 · lead sponsor · 2019-05-08

ACTIVE_NOT_RECRUITING

A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung CancerNCT03258788 · lead sponsor · 2019-01-03

Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine CarcinomaNCT03837977 · lead sponsor · 2018-11-13

Magnetic Resonance Imaging (MRI) for the Delineation of Organs At Risk (OAR) and Target Volumes in Lung Cancer PatientsNCT03048760 · lead sponsor · 2017-09-11

Respiratory Distress Symptom Intervention (RDSI) TrialNCT03223805 · lead sponsor · 2017-04-04

Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple MyelomaNCT02275403 · lead sponsor · 2015-04-13

Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate CancerNCT02424448 · lead sponsor · 2014-12-01

The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility StudyNCT01842750 · lead sponsor · 2013-08-01

MEK Inhibitor and Thoracic Radiotherapy TrialNCT01146756 · lead sponsor · 2010-06-04

Window Study of ZD4054 in Metastatic Prostate CancerNCT01168141 · lead sponsor · 2009-07-01

Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung CancerNCT00433563 · lead sponsor · 2008-04-01

Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological CancerNCT00601406 · lead sponsor · 2006-03-01

Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or CarboplatinNCT00055965 · lead sponsor · 2002-11-01

Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT00022009 · lead sponsor · 2001-07-01

Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During SurgeryNCT00004887 · lead sponsor · 1999-01-01

Temozolomide in Treating Women With Advanced Breast CancerNCT00005054 · lead sponsor · 1998-05-01

Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLCNCT07718243 · collaborator · 2026-08-28

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyNCT04075305 · collaborator · 2019-02-01

Enhanced Monitoring for Better Recovery and Cancer Experience in Greater ManchesterNCT05099237 · collaborator · 2021-12-01

ARtificial Intelligence for Gross Tumour vOlume SegmentationNCT05775068 · collaborator · 2021-07-01

What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study ProtocolNCT04359420 · collaborator · 2019-08-01

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaNCT03654833 · collaborator · 2019-01-28

The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver MetastasesNCT03562234 · collaborator · 2018-10-22

Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.NCT03644303 · collaborator · 2018-08-13

Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by SurgeryNCT00410683 · collaborator · 2007-02-01

Drugs studied in this sponsor's trials

16 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing The Christie NHS Foundation Trust as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

aspirin2

avelumab2

carboplatin2

cisplatin2

gemcitabine hydrochloride2

abemaciclib1

docetaxel1

fluorouracil1

aspirin RxCUI 1191 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials avelumab RxCUI 1875534 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials carboplatin RxCUI 40048 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials cisplatin RxCUI 2555 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials gemcitabine hydrochloride RxCUI 236234 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials abemaciclib RxCUI 1946825 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fluorouracil RxCUI 4492 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ifosfamide RxCUI 5657 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lansoprazole RxCUI 17128 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial leucovorin RxCUI 6313 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial mitomycin RxCUI 632 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial rucaparib RxCUI 1862579 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial temozolomide RxCUI 37776 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial vinblastine sulfate RxCUI 11199 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor27

collaborator9

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.